Medroxyprogesterone acetate (Synonyms: NSC 21171, NSC 26386, U-8839) |
| Catalog No.GC12974 |
Medroxyprogesterone acetate (MPA) is a synthetic progestin.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 71-58-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Medroxyprogesterone acetate (MPA) is a synthetic progestin[1]. Medroxyprogesterone acetate can be used for contraception, endometriosis, endometrial bleeding, and can also be used to treat endometrial cancer and breast cancer[2, 3].
In vitro, treatment of human colon cancer cell lines HT29 and HCT116 cells with Medroxyprogesterone acetate (20nM) for 48h reduced the level of cyclin E and led to G1 phase arrest of cells[4]. Treatment of human endothelial cells with Medroxyprogesterone acetate (0.5, 10nM) for 16h inhibited the expression of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), and reduced the adhesion of endothelial cells to leukocytes[5].
In vivo, oral treatment of ovariectomized mice with Medroxyprogesterone acetate (0.05, 0.1, and 0.2mg/kg/day) for 14 days increased allopregnanolone levels in all tissues except the adrenal glands and affected β-END levels in the hippocampus and interneuronal lobe[6]. Intramuscular treatment of mice with KPL-4 cell xenografts with Medroxyprogesterone acetate (100mg/kg) significantly reduced serum IL-6 levels but did not affect tumor growth[7].
References:
[1] Mattson R H, Cramer J A, Caldwell B V, et al. Treatment of seizures with medroxyprogesterone acetate: preliminary report[J]. Neurology, 1984, 34(9): 1255-1255.
[2] Kaunitz A M. Long-acting injectable contraception with depot medroxyprogesterone acetate[J]. American journal of obstetrics and gynecology, 1994, 170(5): 1543-1549.
[3] Kim J J, Kurita T, Bulun S E. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer[J]. Endocrine reviews, 2013, 34(1): 130-162.
[4] Tanaka Y, Kato K, Mibu R, et al. Medroxyprogesterone acetate inhibits proliferation of colon cancer cell lines by modulating cell cycle-related protein expression[J]. Menopause, 2008, 15(3): 442-453.
[5] Simoncini T, Mannella P, Fornari L, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells[J]. Endocrinology, 2004, 145(12): 5745-5756.
[6] Bernardi F, Pluchino N, Pieri M, et al. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels[J]. Neuroendocrinology, 2006, 83(5-6): 348-359.
[7] Kurebayashi J, Yamamoto S, Otsuki T, et al. Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect[J]. British journal of cancer, 1999, 79(3): 631-636.
| Cell experiment [1]: | |
Cell lines | HT29、HCT116 cells |
Preparation Method | Cells were plated on 10-cm dishes at a density of 1×106/well. After 24h, the cells were stimulated in phenol red-free medium containing 10% charcoal treated fetal bovine serum supplemented with 20nM Medroxyprogesterone acetate (MPA) or vehicle. After 48h, the cells were washed twice with cold phosphate-buffered saline and then lysed with RIPA buffer and protease inhibitor cocktail. The samples were electrophoresed and transferred onto a nitrocellulose membrane. The membranes were immunoblotted with anti-cyclin D1 antibody and anti-cyclin E antibody and analyzed by using an ECL Western blotting detection kit. |
Reaction Conditions | 20nM; 48h |
Applications | Medroxyprogesterone acetate decreases the level of cyclin E, contributing to the G1 arrest in HT29 and HCT116 cells. |
| Animal experiment [2]: | |
Animal models | Female Wistar rats |
Preparation Method | Thirteen groups of Wistar ovariectomized rats received one of the following treatments: oral Progesterone (2, 4 or 8mg/kg/day); oral Medroxyprogesterone acetate (0.05, 0.1 or 0.2mg/kg/day); Estradiol valerate (0.05mg/kg/day); Estradiol valerate+progesterone (0.05mg/kg/day+2, 4 or 8mg/kg/day), or Estradiol valerate+Medroxyprogesterone acetate (0.05mg/kg/day+0.05, 0.1 or 0.2mg/kg/day) for 14 days. One group of fertile and one group of ovariectomized rats were used as controls. The concentration of allopregnanolone was assessed in the frontal and parietal lobes, hypothalamus, hippocampus, anterior pituitary, adrenals and serum, while the beta-END content was assessed in the frontal and parietal lobes, hypothalamus, hippocampus, anterior and neurointermediate pituitary, and plasma. |
Dosage form | 0.05, 0.1, 0.2mg/kg/day for 14 days; p.o. |
Applications | Medroxyprogesterone acetate increased allopregnanolone levels in all tissues except the adrenal glands. Medroxyprogesterone acetate only affected β-END levels in the hippocampus and interneuronal lobe. |
References: | |
| Cas No. | 71-58-9 | SDF | |
| Synonyms | NSC 21171, NSC 26386, U-8839 | ||
| Chemical Name | [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate | ||
| Canonical SMILES | CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C | ||
| Formula | C24H34O4 | M.Wt | 386.52 |
| Solubility | ≥ 9.5mg/mL in DMSO with gentle warming | Storage | Store at 4°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5872 mL | 12.9359 mL | 25.8719 mL |
| 5 mM | 0.5174 mL | 2.5872 mL | 5.1744 mL |
| 10 mM | 0.2587 mL | 1.2936 mL | 2.5872 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *